CoChat

Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)

Akhtari, Mojtaba, Waller, Edmund K., Jaye, David L., Lawson, David H., Ibrahim, Ramy, Papadopoulos, Nicholas E., Arellano, Martha L. · 2009 · Journal of Immunotherapy
Cited by 89

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

A 42-year-old white woman with a diagnosis of metastatic melanoma developed severe neutropenia during treatment with ipilimumab (anticytotoxic T-lymphocyte-associated antigen-4 antibody). Bone marrow aspiration and biopsy specimens revealed marked myeloid hypoplasia, with unremarkable erythropoiesis and megakaryopoiesis. The patient's neutropenia did not respond to therapy with a combination of colony stimulating factors and steroids; however, it rapidly improved after administration of intravenous immunoglobulin. Treatment with ipilimumab has not been reported to be associated with hematologic toxicities, and to our knowledge, no case of neutropenia has previously been reported. This report of acute grade 4 neutropenia associated with ipilimumab and clinically consistent with an autoimmune process emphasizes the importance of monitoring complete blood count during treatment with this new monoclonal antibody.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/cji.0b013e31819aa40b

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 89

Metadata

Authors
Akhtari, M., Waller, E. K., Jaye, D. L., Lawson, D. H., Ibrahim, R., Papadopoulos, N. E., & Arellano, M. L.
Venue
Journal of Immunotherapy
Published
2009-04
Volume
32
Issue
3
Pages
322-324
ISSN
1524-9557 (ISSN-L)
OpenAlex
W2086264703
Cited by
89
References
4
FWCI
1.49
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody). https://app.cochat.ai/papers/10.1097/cji.0b013e31819aa40b
The paper
Akhtari, M., Waller, E. K., Jaye, D. L., Lawson, D. H., Ibrahim, R., Papadopoulos, N. E., & Arellano, M. L. (2009). Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody). Journal of Immunotherapy. https://doi.org/10.1097/cji.0b013e31819aa40b

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.